A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Public ClinicalTrials.gov record NCT07063212. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Sacituzumab Govitecan in Combination With Cetuximab in Patients With Recurrent Metastatic HNSCC That Has Progressed After First-Line Therapy
Study identification
- NCT ID
- NCT07063212
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 40 participants
Conditions and interventions
Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Hypopharynx Cancer
- Hypopharynx Squamous Cell Carcinoma
- Larynx Cancer
- Larynx Squamous Cell Carcinoma
- Nasal Cavity Cancer
- Oral Cavity Cancer
- Oral Squamous Cell Carcinoma
- Oropharynx Cancer
- Oropharynx Squamous Cell Carcinoma
- Sinus Cancer
- Squamous Cell Carcinoma of Head and Neck
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1, 2025
- Primary completion
- Jan 1, 2028
- Completion
- Jan 1, 2028
- Last update posted
- Feb 18, 2026
2025 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 2
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | 07748 | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | 07645 | Recruiting |
| Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) | Commack | New York | 11725 | Recruiting |
| Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison | New York | 10604 | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activites) | New York | New York | 10065 | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | New York | 11553 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated HPV Positive Oropharyngeal Squamous Cell Carcinoma trials
Other public records listing HPV Positive Oropharyngeal Squamous Cell Carcinoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07797738: Prognostic Biomarkers for Patients With Human Papillomavirus (HPV) Positive Oropharyngeal Squamous Cell Carcinoma Not yet recruiting
- NCT05119036: Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma Active, not recruiting
- NCT07497607: Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma Recruiting
- NCT07172256: CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs Recruiting
- NCT04502407: Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer Active, not recruiting
- NCT05600842: De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx Recruiting
All HPV Positive Oropharyngeal Squamous Cell Carcinoma trials →
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07063212, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 18, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07063212 live on ClinicalTrials.gov.